Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.
BRAF
COVID-19
MEK
Targeted
Treatment
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
12
07
2020
revised:
07
08
2020
accepted:
10
08
2020
pubmed:
19
9
2020
medline:
9
2
2021
entrez:
18
9
2020
Statut:
ppublish
Résumé
Histiocytic disorders are an exceptionally rare group of diseases with diverse manifestations and a paucity of approved treatments, thereby leading to various challenges in their diagnosis and management. With the discovery of novel molecular targets and the incorporation of targeted agents in the management of various adult histiocytic disorders, their management has become increasingly complex. In an attempt to improve the understanding of the clinical features and management of common adult histiocytic disorders (Langerhans cell histiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease, and hemophagocytic lymphohistiocytosis), we created this document based on existing literature and expert opinion.
Identifiants
pubmed: 32943371
pii: S2152-2650(20)30422-5
doi: 10.1016/j.clml.2020.08.007
pmc: PMC7434330
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e66-e75Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2020 May 7;382(19):1811-1822
pubmed: 32374962
Rheumatology (Oxford). 2019 Jan 1;58(1):5-17
pubmed: 29481673
Am J Clin Pathol. 2016 Jun;145(6):862-70
pubmed: 27298397
Orphanet J Rare Dis. 2013 May 14;8:72
pubmed: 23672541
Blood. 2014 Jul 24;124(4):483-92
pubmed: 24850756
Mediterr J Hematol Infect Dis. 2013 Apr 10;5(1):e2013022
pubmed: 23667720
Nature. 2019 Mar;567(7749):521-524
pubmed: 30867592
Blood. 2015 May 7;125(19):2908-14
pubmed: 25758828
Pediatr Blood Cancer. 2008 Jun;50(6):1227-35
pubmed: 18085676
Cancer. 2018 Jun 15;124(12):2607-2620
pubmed: 29624648
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265
Can Respir J. 2010 May-Jun;17(3):e55-62
pubmed: 20617216
Pediatr Blood Cancer. 2013 Jan;60(1):101-9
pubmed: 22522603
J Obstet Gynaecol. 2020 Feb;40(2):153-159
pubmed: 31215279
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Pediatr Blood Cancer. 2016 Feb;63(2):358-60
pubmed: 26452062
Case Rep Hematol. 2017;2017:3862052
pubmed: 29214086
Am J Hematol. 2021 May 1;96(5):E146-E150
pubmed: 33539584
Haematologica. 2020 Jan 31;105(2):348-357
pubmed: 31004029
BMC Med. 2020 Jul 15;18(1):214
pubmed: 32664932
Blood. 2018 Jun 28;131(26):2877-2890
pubmed: 29720485
J Postgrad Med. 2015 Apr-Jun;61(2):112-5
pubmed: 25766345
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1
pubmed: 32411313
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Mayo Clin Proc. 2019 Oct;94(10):2054-2071
pubmed: 31472931
Blood Adv. 2019 Apr 9;3(7):934-938
pubmed: 30917949
JAMA Oncol. 2018 Mar 01;4(3):384-388
pubmed: 29188284
Blood. 2011 Oct 27;118(17):4577-84
pubmed: 21900192
Ann Hematol. 2014 May;93(5):821-6
pubmed: 24705932
Blood. 2020 May 28;135(22):1929-1945
pubmed: 32187362
Case Rep Oncol. 2018 Jan 19;11(1):55-62
pubmed: 29515411
Rheumatology (Oxford). 2019 Nov 1;58(Suppl 6):vi9-vi22
pubmed: 31769856
Hematol Rep. 2015 Sep 23;7(3):6100
pubmed: 26487936
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
Med Hypotheses. 2020 Sep;142:109826
pubmed: 32416415
Front Immunol. 2013 Dec 12;4:441
pubmed: 24376445
Ann Oncol. 2010 Jun;21(6):1173-1178
pubmed: 19861578
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Pediatr Blood Cancer. 2013 Feb;60(2):175-84
pubmed: 23109216